Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Santen Pharmaceutical Co ( (JP:4536) ) has shared an update.
Santen Pharmaceutical Co. reported a decline in its financial performance for the six months ended September 30, 2025, with revenue and profits decreasing compared to the previous year. Despite the downturn, the company plans to maintain its dividend payments and has resolved to cancel treasury shares, indicating a strategic focus on shareholder value.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily operating in the pharmaceutical industry. The company focuses on eye care products and services, catering to a global market.
Average Trading Volume: 1,518,848
Technical Sentiment Signal: Buy
Current Market Cap: Yen520.3B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.